Compare TT & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TT | BMY |
|---|---|---|
| Founded | 1885 | 1887 |
| Country | Ireland | United States |
| Employees | N/A | 32500 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7B | 113.5B |
| IPO Year | 2009 | N/A |
| Metric | TT | BMY |
|---|---|---|
| Price | $484.75 | $56.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $489.38 | $61.73 |
| AVG Volume (30 Days) | 1.3M | ★ 11.9M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | 0.88% | ★ 4.38% |
| EPS Growth | ★ 15.48 | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $14,782,000,000.00 | N/A |
| Revenue This Year | $12.12 | N/A |
| Revenue Next Year | $8.06 | N/A |
| P/E Ratio | $182.49 | ★ $17.26 |
| Revenue Growth | ★ 5.58 | N/A |
| 52 Week Low | $348.06 | $42.52 |
| 52 Week High | $505.87 | $62.89 |
| Indicator | TT | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 50.85 |
| Support Level | $403.25 | $56.36 |
| Resistance Level | $504.67 | $57.43 |
| Average True Range (ATR) | 15.10 | 1.45 |
| MACD | 0.31 | 0.26 |
| Stochastic Oscillator | 49.82 | 62.32 |
Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for approximately 80% of its revenue, with 13% from EMEA and 7% Asia-Pacific. The company was formed in 2020 when its former parent, Ingersoll Rand, merged with Gardner Denver in a tax-advantaged reverse Morris trust transaction.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.